Regeneron Pharmaceuticals Inc.

About Us

Bharti Rana Jayshankar – Founder

She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.

Jay Shankar – Co-founder

He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.

Contact Info

info@healthquill.com

Regeneron Pharmaceuticals, Inc.’s drug for a type of blood cancer in patients who have received four treatments before, and the disease has recurred, has received the US regulator’s green light.

Regenron’s drug to treat a type of blood cancer gets US regulator’s nod

HQ Team June 3, 2025: Regeneron Pharmaceuticals, Inc.’s drug for a type of blood cancer in patients who have received four treatments before,.

by HealthQuill
July 3, 2025
0 Comments

Regeneron Pharmaceuticals, Inc. will pay China’s Hansoh Pharmaceuticals Group Company Limited $80 million upfront to acquire rights for a weight-loss drug candidate.

Drugs Health Pharma

Regeneron to pay China’s Hansoh $80m upfront for weight-loss drug

HQ Team June 2, 2025: Regeneron Pharmaceuticals, Inc. will pay China’s Hansoh Pharmaceuticals Group Company Limited $80 million upfront to acquire rights for.